Appropriate use of anabolic treatment for severe osteoporosis

Clinical Cases in Mineral and Bone Metabolism

Volumn 7, Issue 2, 2010, Pages 114-122

  Adami, Silvano ^a   Brandi, Maria Luisa ^b   Canonico, Pier Luigi ^c   Minisola, Giovanni ^d   Minisola, Salvatore ^e   Tarantino, Umberto ^f  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^d SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f UNIVERSITY OF ROME   (Italy)

Author keywords

Antiresorptives; Cost effectiveness; Fractures; Severe osteoporosis; Teriparatide

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; ZOLEDRONIC ACID;

BONE DENSITY; CORTICAL BONE; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; LIFE EXPECTANCY; NON VERTEBRA FRACTURE; OSTEOPOROSIS; QUALITY OF LIFE; RISK REDUCTION; SHORT SURVEY; TRABECULAR BONE; VERTEBRA FRACTURE;

EID: 78449247509     PISSN: 17248914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (51)

1. Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D. Risk of mortality following clinical fractures. Osteoporos Int 2000; 11: 556-61.
2. Johnell O, Kanis JA, Oden A, et al. Mortality after osteoporotic fractures. Osteoporos Int 2004; 15: 38-42.
3. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006; 17 (12): 1726-33. (Pubitemid 44607392)
4. Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A. How to decide who to treat. Best Pract Res Clin Rheumatol 2009; 23 (6): 711-26.
5. rd, Stock JL. Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocrine Rev 2002; 23: 16-37.
6. Guyatt GH, Cranney A, Griffith L, Walter S, Krolicki N, Favus M, Rosen C. Summary of meta-analyses of therapies for postmenopausal osteoporosis and the relationship between bone density and fractures. Endocrinol Metab Clin North Am 2002; 31 (3): 659-79, xii.
7. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348: 1535-41.
8. Harris ST, Watts NB, Genant HK, et al. for the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999; 282: 1344-52.
9. Reginster J, Minne HW, Sorensen OH, et al. on behalf of the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000; 11: 83-91.
10. Ettinger B, Black DM, Mitlak BH, et al. for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999; 282: 637-45.
11. Chesnut III CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD; Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004 Aug;19(8):1241-9. Epub 2004 Mar 29.
12. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004; 350: 459-468. (Pubitemid 38133766)
13. Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab. 2005 May;90(5):2816-22.
14. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR; HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007 May 3;356(18):1809-22.
15. Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, Licata A, Benhamou L, Geusens P, Flowers K, Stracke H, Seeman E. Risk of new vertebral fracture in the year following a fracture. JAMA 2001; 285 (3): 320-3.
16. Nevitt MC, Ross PD, Palermo L, Musliner T, Genant HK, Thompson DE. Association of prevalent vertebral fractures, bone density, and alendronate treatment with incident vertebral fractures: effect of number and spinal location of fractures. The Fracture Intervention Trial Research Group. Bone 1999; 25 (5): 613-9. (Pubitemid 29469470)
17. Siris ES, Selby PL, Saag KG, Borgström F, Herings RM, Silverman SL. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 2009; 122 (2 Suppl): S3-13. Review.
18. Adami S, Isaia G, Luisetto G, Minisola S, Sinigaglia L, Silvestri S, Agnusdei D, Gentilella R, Nuti R on behalf of ICARO Study Group. Osteoporosis treatment and fracture incidence: the ICARO longitudinal study. Osteoporos Int 2008; 19: 1219-1223.
19. Adami S, Isaia G, Luisetto G, Minisola S, Sinigaglia L, Gentilella R, Agnusdei D, Iori N, Nuti R on behalf of ICARO Study Group. Fracture Incidence and Characterization in Patients on Osteoporosis Treatment: The ICARO Study. J Bone Miner Res 2006; 21: 1565-1570.
20. Agenzia Italiana per il Farmaco: AIFA. Available at: http://www. agenziafarmaco.it/
21. Delmas PD, Genant HK, Crans GG, et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 2003; 33: 522-32.
22. Johnel O, Kanis JA, Oden A, Sernbo, Redlund-Johnel I, Petterson C, De Laet C, B Jonsson. Fracture risk following an osteoporotic fracture. Osteoporosis Int 2004; 15: 175-9.
23. Melton LJ, Lane AW, Cooper C. Prevalence and incidence of vertebral deformities. Osteoporos Int 1993; 3: 113-9.
24. Ross PD, Genant HK, Davis JW. Predicting vertebral fracture incidence from prevalent vertebral fractures and bone density among non-black, osteoporotic women. Osteoporos Int 1993, 3: 120-6.
25. Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK. The components of excess mortality after hip fracture. Bone. 2003; 32 (5): 468-73.
26. Kanis JA, Oden A, Johnell A, De Laet A, Jonsson B. Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 2004; 15: 108-112.
27. Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone. 2000; 27(5): 687-94.
28. Meunier J Boivin G, Meunier PJ. Effects of bisphosphonates on matrix mineralization. Musculoskelet Neuronal Interact 2002; 2(6): 538-43.
29. Arlot M, Meunier PJ, Boivin G. Differential Effects of Teriparatide and Alendronate on Bone Remodeling in Postmenopausal Women Assessed by Histomorphometric Parameters. J Bone Miner Res 2005; 20: 1244-1253. (Pubitemid 40863814)
30. Ma YL, Zeng Q, Donley DW, Ste-Marie LG, Gallagher JC, Dalsky GP, Marcus R, Eriksen EF. Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J Bone Miner Res 2006; 21 (6): 855-64. (Pubitemid 43787992)
31. Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF. Teriparatide [recombinant human parathyroid hormone (1-34)] improves both cortical and cancellous bone structure. J Bone Miner Res 2003; 18: 1932-1941
32. Borggrefe J, Graeff C, Nickelsen TN, Marin F, Glüer CC. Quantitative Computed Tomography Assessment of the Effects of 24 months of Teriparatide Treatment on 3-D Femoral Neck Bone Distribution, Geometry and Bone Strength: Results from the EUROFORS Study. JBMR 2010; 25(3): 472-481.
33. Graeff C, Chevalier Y, Charlebois M, Varga P, Pahr D, Nickelsen TN, Morlock MM, Glüer CC, Zysset PK. Improvements in Vertebral Body Strength Under Teriparatide Treatment Assessed In Vivo by Finite Element Analysis: Results From the EUROFORS Study. J Bone Miner Res 2009; 24: 1672-1680.
34. Lindsay R, Scheele WH, Neer R, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide [recombinant human parathyroid hormone (1-34)] in postmenopausal women with osteoporosis. Arch Intern Med 2004; 164: 2024-30.
35. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-41.
36. Gallagher JC, Genant HK, Crans GG, Vargas SJ, and Krege JH. Teriparatide Reduces the Fracture Risk Associated with Increasing Number and Severity of Osteoporotic Fractures. J Clin Endocrinol Metab 2005; 90: 1583-1587.
37. Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, Dalsky GP, Marcus R. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med Nov 2007; 15; 357(20): 2028-39.
38. Lindsay R, Miller P, Pohl G, Glass EV, Chen P, Krege JH. Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis. Osteoporos Int 2008, DOI 10.1007/s00198-008-0766-0.
39. Eastell R. Thomas Nickelsen, Fernando Marin, Clare Barker, Peyman Hadji, Jordi Farrerons, Maurice Audran, Steven Boonen, Kim Brixen, Jose Melo Gomes, Barbara Obermayer-Pietsch, Avraam Avramidis, Gunnar Sigurdsson, and Claus C Glüer Sequential Treatment of Severe Postmenopausal Osteoporosis After Teriparatide: Final Results of the Randomized, Controlled European Study of Forsteo (EUROFORS) J Bone Miner Res 2009: 24: 726-736.
40. Langdahl BL, Rajzbaum G, Jakob F, Karras D, Ljunggren O, Lems WF, Fahrleitner-Pammer A, Walsh JB, Barker C, Kutahov A, Marin F. Reduction in Fracture Rate and Back Pain and Increased Quality of Life in Postmenopausal Women Treated with Teriparatide: 18-Month Data from the European Forsteo Observational Study (EFOS). Calcif Tissue Int 2009; 85: 484-493.
41. Watts NB, Chines A, Olszynski WP, McKeever CD, McClung MR, Zhou X, Grauer A. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int. 2008; 19(3): 365-72.
42. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR; FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006; 296(24): 2927-38.
43. Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333(22): 1437-43.
44. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002 Jul 17;288(3):321-33.
45. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1995; 122(1): 9-16.
46. The Writing Group for the PEPI . Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1996; 276(17): 1389-96.
47. Prince R, Sipos A, Hossain A, Syversen U, Ish-Shalom S, Marcinowska E, Halse J, Lindsay R, Dalsky GP, and Mitlak BH. Sustained Nonvertebral Fragility Fracture Risk Reduction After Discontinuation of Teriparatide Treatment. J Bone Miner Res 2005; 20: 1507-1513. (Pubitemid 41243539)
48. Adami S, San Martin J, Muñoz-Torres M, Econs MJ, Xie L, Dalsky GP, McClung M, Felsenberg D, Brown JP, Brandi ML, Sipos A. Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis. Osteoporos Int 2008; 19: 87-94.
49. Cosman F, Wermers RA, Recknor C, Mauck KF, Xie L, Glass EV, and Krege JH. Effects of Teriparatide in Postmenopausal Women with Osteoporosis on Prior Alendronate or Raloxifene: Differences between Stopping and Continuing the Antiresorptive Agent. J Clin Endocrinol Metab 2009; 94: 3772-3780.
50. Gjertsen JE, Vinje T, Lie SA, Engesæter LB, Havelin LI, Furnes O, and Fevang JM. Patient satisfaction, pain, and quality of life 4 months after displaced femoral neck fractures. Acta Orthopaedica 2008; 79 (5): 594-601.
51. Piscitelli P, Iolascon G, Gimigliano F, Muratore M, Camboa P, Borgia O, Forcina B, Fitto F, Robaud V, Termini G, Rini GB, Gianicolo E, Faino A, Rossini M, Adami S, Angeli A, Distante A, Gatto S, Gimigliano R, Guida G, on the behalf of the SIOMMMS study group and the CERSUM research group. Incidence and costs of hip fractures compared to acute myocardial infarction in the Italian population: a 4-year survey. Osteoporos Int 2007; 18: 211-219.